Brought to you by 
Mallinckrodt purchases pain drug Roxicodone from Xanodyne
18 Nov 2022
Executive Summary
Continuing to strengthen its portfolio in preparation for a spin off from Covidien PLC’s Covidien Ltd., Mallinckrodt LLC (branded and generic pain and addiction treatments) has acquired Roxicodone (oxycodone, 5, 15, and 30 mg dosages) from Xanodyne Pharmaceuticals Inc. (formerly focused on pain management). The transaction includes all rights to the drug’s NDA.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Mallinckrodt purchases pain drug Roxicodone from Xanodyne
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice